Acute Selective Serotonin Reuptake Inhibitors Increase Conditioned Fear Expression: Blockade With a 5-HT2C Receptor Antagonist

Nesha S. Burghardt, David E A Bush, Bruce S. McEwen, Joseph Ledoux

Research output: Contribution to journalArticle

Abstract

Background: Selective serotonin reuptake inhibitors (SSRIs) effectively treat various anxiety disorders, although symptoms of anxiety are often exacerbated during early stages of treatment. We previously reported that acute treatment with the SSRI citalopram enhances the acquisition of auditory fear conditioning, which is consistent with the initial anxiogenic effects reported clinically. Here, we extend our findings by assessing the effects of acute SSRI treatment on the expression of previously acquired conditioned fear. Methods: Rats underwent fear conditioning drug-free. Tone-evoked fear responses were tested after drug treatment the following day. This protocol more closely resembles the clinical setting than pre-conditioning treatment, because it evaluates effects of treatment on a pre-existing fear rather than on the formation of a new fear memory. Results: A single pre-testing injection of the SSRIs citalopram or fluoxetine significantly increased fear expression. There was no effect of the antidepressant tianeptine or the norepinephrine reuptake inhibitor tomoxetine, indicating that this effect is specific to SSRIs. The SSRI-induced enhancement in fear expression was not blocked by tropisetron, a 5-HT3 receptor antagonist, but was blocked by SB 242084, a specific 5-HT2C receptor antagonist. Conclusions: Enhanced activation of 5-HT2C receptors might be a mechanism for the anxiogenic effects of SSRIs observed initially during treatment.

Original languageEnglish (US)
Pages (from-to)1111-1118
Number of pages8
JournalBiological Psychiatry
Volume62
Issue number10
DOIs
StatePublished - Nov 15 2007

Fingerprint

Receptor, Serotonin, 5-HT2C
Serotonin 5-HT2 Receptor Antagonists
Serotonin Uptake Inhibitors
Fear
Citalopram
tianeptine
tropisetron
Therapeutics
Serotonin 5-HT3 Receptor Antagonists
Receptors, Serotonin, 5-HT3
Fluoxetine
Anxiety Disorders
Pharmaceutical Preparations
Antidepressive Agents
Norepinephrine
Anxiety
Injections

Keywords

  • 5-HT receptor
  • 5-HT receptor
  • Amygdala
  • citalopram
  • fear conditioning
  • serotonin

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Acute Selective Serotonin Reuptake Inhibitors Increase Conditioned Fear Expression : Blockade With a 5-HT2C Receptor Antagonist. / Burghardt, Nesha S.; Bush, David E A; McEwen, Bruce S.; Ledoux, Joseph.

In: Biological Psychiatry, Vol. 62, No. 10, 15.11.2007, p. 1111-1118.

Research output: Contribution to journalArticle

@article{c7b52903955049c2a14394bcffc40386,
title = "Acute Selective Serotonin Reuptake Inhibitors Increase Conditioned Fear Expression: Blockade With a 5-HT2C Receptor Antagonist",
abstract = "Background: Selective serotonin reuptake inhibitors (SSRIs) effectively treat various anxiety disorders, although symptoms of anxiety are often exacerbated during early stages of treatment. We previously reported that acute treatment with the SSRI citalopram enhances the acquisition of auditory fear conditioning, which is consistent with the initial anxiogenic effects reported clinically. Here, we extend our findings by assessing the effects of acute SSRI treatment on the expression of previously acquired conditioned fear. Methods: Rats underwent fear conditioning drug-free. Tone-evoked fear responses were tested after drug treatment the following day. This protocol more closely resembles the clinical setting than pre-conditioning treatment, because it evaluates effects of treatment on a pre-existing fear rather than on the formation of a new fear memory. Results: A single pre-testing injection of the SSRIs citalopram or fluoxetine significantly increased fear expression. There was no effect of the antidepressant tianeptine or the norepinephrine reuptake inhibitor tomoxetine, indicating that this effect is specific to SSRIs. The SSRI-induced enhancement in fear expression was not blocked by tropisetron, a 5-HT3 receptor antagonist, but was blocked by SB 242084, a specific 5-HT2C receptor antagonist. Conclusions: Enhanced activation of 5-HT2C receptors might be a mechanism for the anxiogenic effects of SSRIs observed initially during treatment.",
keywords = "5-HT receptor, 5-HT receptor, Amygdala, citalopram, fear conditioning, serotonin",
author = "Burghardt, {Nesha S.} and Bush, {David E A} and McEwen, {Bruce S.} and Joseph Ledoux",
year = "2007",
month = "11",
day = "15",
doi = "10.1016/j.biopsych.2006.11.023",
language = "English (US)",
volume = "62",
pages = "1111--1118",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "10",

}

TY - JOUR

T1 - Acute Selective Serotonin Reuptake Inhibitors Increase Conditioned Fear Expression

T2 - Blockade With a 5-HT2C Receptor Antagonist

AU - Burghardt, Nesha S.

AU - Bush, David E A

AU - McEwen, Bruce S.

AU - Ledoux, Joseph

PY - 2007/11/15

Y1 - 2007/11/15

N2 - Background: Selective serotonin reuptake inhibitors (SSRIs) effectively treat various anxiety disorders, although symptoms of anxiety are often exacerbated during early stages of treatment. We previously reported that acute treatment with the SSRI citalopram enhances the acquisition of auditory fear conditioning, which is consistent with the initial anxiogenic effects reported clinically. Here, we extend our findings by assessing the effects of acute SSRI treatment on the expression of previously acquired conditioned fear. Methods: Rats underwent fear conditioning drug-free. Tone-evoked fear responses were tested after drug treatment the following day. This protocol more closely resembles the clinical setting than pre-conditioning treatment, because it evaluates effects of treatment on a pre-existing fear rather than on the formation of a new fear memory. Results: A single pre-testing injection of the SSRIs citalopram or fluoxetine significantly increased fear expression. There was no effect of the antidepressant tianeptine or the norepinephrine reuptake inhibitor tomoxetine, indicating that this effect is specific to SSRIs. The SSRI-induced enhancement in fear expression was not blocked by tropisetron, a 5-HT3 receptor antagonist, but was blocked by SB 242084, a specific 5-HT2C receptor antagonist. Conclusions: Enhanced activation of 5-HT2C receptors might be a mechanism for the anxiogenic effects of SSRIs observed initially during treatment.

AB - Background: Selective serotonin reuptake inhibitors (SSRIs) effectively treat various anxiety disorders, although symptoms of anxiety are often exacerbated during early stages of treatment. We previously reported that acute treatment with the SSRI citalopram enhances the acquisition of auditory fear conditioning, which is consistent with the initial anxiogenic effects reported clinically. Here, we extend our findings by assessing the effects of acute SSRI treatment on the expression of previously acquired conditioned fear. Methods: Rats underwent fear conditioning drug-free. Tone-evoked fear responses were tested after drug treatment the following day. This protocol more closely resembles the clinical setting than pre-conditioning treatment, because it evaluates effects of treatment on a pre-existing fear rather than on the formation of a new fear memory. Results: A single pre-testing injection of the SSRIs citalopram or fluoxetine significantly increased fear expression. There was no effect of the antidepressant tianeptine or the norepinephrine reuptake inhibitor tomoxetine, indicating that this effect is specific to SSRIs. The SSRI-induced enhancement in fear expression was not blocked by tropisetron, a 5-HT3 receptor antagonist, but was blocked by SB 242084, a specific 5-HT2C receptor antagonist. Conclusions: Enhanced activation of 5-HT2C receptors might be a mechanism for the anxiogenic effects of SSRIs observed initially during treatment.

KW - 5-HT receptor

KW - 5-HT receptor

KW - Amygdala

KW - citalopram

KW - fear conditioning

KW - serotonin

UR - http://www.scopus.com/inward/record.url?scp=35649017259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35649017259&partnerID=8YFLogxK

U2 - 10.1016/j.biopsych.2006.11.023

DO - 10.1016/j.biopsych.2006.11.023

M3 - Article

VL - 62

SP - 1111

EP - 1118

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 10

ER -